Fine Mapping of Genetic Variants in BIN1, CLU, CR1 and PICALM for Association with Cerebrospinal Fluid Biomarkers for Alzheimer's Disease
Author(s) -
John Kauwe,
Carlos Cruchaga,
Celeste M. Karch,
Brooke Sadler,
Mo Lee,
Kevin H. Mayo,
Wayne Latu,
Manti Su'a,
Anne M. Fagan,
David M. Holtzman,
John C. Morris,
Alison Goate
Publication year - 2011
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0015918
Subject(s) - cerebrospinal fluid , genome wide association study , single nucleotide polymorphism , genotyping , biology , genetic association , alzheimer's disease , disease , genetics , gene , genotype , medicine , neuroscience
Recent genome-wide association studies of Alzheimer's disease (AD) have identified variants in BIN1 , CLU , CR1 and PICALM that show replicable association with risk for disease. We have thoroughly sampled common variation in these genes, genotyping 355 variants in over 600 individuals for whom measurements of two AD biomarkers, cerebrospinal fluid (CSF) 42 amino acid amyloid beta fragments (Aβ 42 ) and tau phosphorylated at threonine 181 (ptau 181 ), have been obtained. Association analyses were performed to determine whether variants in BIN1, CLU, CR1 or PICALM are associated with changes in the CSF levels of these biomarkers. Despite adequate power to detect effects as small as a 1.05 fold difference, we have failed to detect evidence for association between SNPs in these genes and CSF Aβ 42 or ptau 181 levels in our sample. Our results suggest that these variants do not affect risk via a mechanism that results in a strong additive effect on CSF levels of Aβ 42 or ptau 181 .
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom